Collaborative Arrangements and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2020

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2020 and 2019, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
SPINRAZA royalties (commercial revenue)	$	71.7		$	70.5		$	137.8		$	130.2
R&D revenue		26.0			31.9			47.4			56.4
Total revenue from our relationship with Biogen	$	97.7		$	102.4		$	185.2		$	186.6
Percentage of total revenue		67	%		63	%		66	%		41	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2020 and 2019, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
R&D revenue	$	16.8		$	3.8		$	30.5		$	7.8
Percentage of total revenue		12	%		2	%		11	%		2	%